Understanding Ozempic® Shortages and Insurance Issues – Technologist

Ozempic® (semaglutide) is a widely used medication for treating type 2 diabetes and obesity. However, in recent times, there has been a significant shortage of Ozempic® and its related drug, Wegovy®. This shortage can be attributed to various factors, including high demand and supply chain issues, which have made it challenging for patients to access these crucial medications.

What Are the Alternatives During Ozempic® Shortages?

Compounding Pharmacies: A Solution?

One potential solution during drug shortages is the use of compounding pharmacies. These pharmacies create personalized formulations of medications, which can help address the gaps caused by supply shortages. However, compounding semaglutide, the active ingredient in Ozempic®, is not without its challenges.

What Are the Risks of Compounded Semaglutide?

The FDA has issued warnings about the use of compounded semaglutide due to safety concerns. Specifically, compounded versions may not meet federal law requirements, and the salt forms of semaglutide used in these compounds often fail to comply with necessary regulations . This can result in significant safety and efficacy issues for patients.

How Does Federal Scrutiny Impact Compounded Pharmaceuticals?

What Is the FDA’s Role?

Compounded drugs are not subjected to the same stringent approval processes as FDA-approved medications. While the active ingredients in these drugs might be FDA-approved, the compounded preparations themselves do not undergo the same level of scrutiny for safety and efficacy. This lack of oversight can lead to several risks.

What Are the Risks of Using Compounded Drugs?

Compounded medications can present various safety risks, including potency problems and contamination. These risks are compounded by the fact that the FDA does not verify the safety and efficacy of compounded preparations. As a result, the FDA closely monitors incidents related to compounded drugs and issues risk alerts to keep healthcare professionals and consumers informed.

Who Is Affected by Insurance Coverage and Supply Issues?

Does Medicare Cover Obesity Medicines?

Medicare generally does not cover medications specifically for obesity. However, some privately run Medicare Advantage or Medigap plans might offer coverage. The variability in insurance coverage can create additional challenges for patients seeking treatment for obesity.

How Does Medicaid Handle Coverage for Obesity Medicines?

Medicaid coverage for obesity medications varies significantly from state to state. This inconsistency can lead to disparities in access to necessary treatments for patients depending on their location and insurance plan .

What Are the Broader Implications of Ozempic® Shortages?

The shortage of Ozempic® and Wegovy® has far-reaching implications. It highlights the critical role of compounding pharmacies in filling supply gaps, albeit with noted safety concerns. Additionally, the shortage underscores the need for consistent insurance coverage to ensure patients can access these vital medications.

Where Can You Learn More?

For more detailed information on these topics and to stay updated on the latest developments, you can visit the following resources:

In conclusion, understanding the complexities surrounding Ozempic® shortages, the role of compounding pharmacies, federal scrutiny, and insurance coverage can help patients navigate these challenges more effectively. For expert advice and guidance on healthcare-related topics, consider reaching out to Inszone Insurance Services.

Executive VP – North American Health Care Practice Leader

Amy Hieatt is an Executive VP – North American Health Care Practice Leader at Inszone Insurance Services, joining Inszone in September 2023. In her role, Amy is responsible for overseeing the strategic direction and day-to-day operations of Inszone’s national healthcare liability vertical, with a strong emphasis on maintaining a customer-centric approach.

Over the past 20+ years, Amy has dedicated her career to the property and casualty insurance sector, focusing extensively on the Medical Professional Liability and Professional Liability sectors. Prior to her role at Inszone, she served as the Managing Director at Connected Risk Solutions (formerly ABRisk Solutions), a national wholesale brokerage. Before that, Amy led Business Development efforts for NORCAL Group’s Admitted and E&S business lines, managing teams across four regional offices nationwide. She initially entered the insurance field on the retail side, holding the position of Executive Vice President at a regional retail agency that specialized in healthcare liability insurance.

 

Amy’s remarkable journey in insurance, spanning over two decades, is marked by her commitment to servant leadership, her impressive track record of achieving growth and retention, and her dedication to mentoring high-performing collaborative teams. Her expertise in the medical professional liability sector has earned her the admiration of her peers, recognizing her as a visionary leader and expert in the field.

 

In her time off, Amy is passionate about outdoor activities, advocating for animal rights, and finds joy in traveling and reading.

Follow Us: